NOLUDAR
LOE ApproachingNDAORALELIXIR
Approved
Jan 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOLUDAR is an oral elixir small-molecule drug originally approved by Roche in 1955. Mechanism of action and specific indications are not publicly disclosed in available data. The product represents a legacy pharmaceutical asset from the mid-20th century.
LOE Approaching
Product is in late-stage lifecycle with minimal commercial activity; career opportunities focused on managed decline and legacy asset optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NOLUDAR currently has zero linked job openings, reflecting its mature, low-growth status within Roche's portfolio. Roles on this product typically focus on maintenance and compliance rather than strategic expansion or innovation.
Brand Manager (Legacy)Field Sales
Worked on NOLUDAR at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.